Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $11.05

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average rating of “Hold” by the fourteen analysts that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $11.0455.

A number of research firms recently weighed in on ENGN. HC Wainwright dropped their price target on shares of enGene from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Morgan Stanley cut shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a research note on Thursday, June 18th. Citigroup lowered shares of enGene from a “market outperform” rating to a “market perform” rating in a report on Friday, May 8th. Wells Fargo & Company reiterated an “equal weight” rating and set a $2.00 target price (down from $25.00) on shares of enGene in a research report on Friday, May 8th. Finally, Piper Sandler downgraded enGene from an “overweight” rating to a “neutral” rating and cut their price target for the company from $7.00 to $4.00 in a research note on Friday, May 8th.

enGene Stock Performance

Shares of NASDAQ:ENGN opened at $1.91 on Friday. The stock has a market capitalization of $127.95 million, a P/E ratio of -0.88 and a beta of -0.28. enGene has a 1-year low of $1.40 and a 1-year high of $12.25. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. The business has a 50-day moving average price of $1.81 and a two-hundred day moving average price of $4.50.

enGene (NASDAQ:ENGN) last released its earnings results on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. During the same quarter last year, the company earned $0.51 EPS. Equities analysts predict that enGene will post -1.84 earnings per share for the current year.

Institutional Investors Weigh In On enGene

A number of institutional investors have recently made changes to their positions in the stock. Cresset Asset Management LLC acquired a new position in enGene in the second quarter valued at about $36,000. Raymond James Financial Inc. boosted its holdings in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of enGene during the 2nd quarter worth about $38,000. Jump Financial LLC acquired a new position in shares of enGene during the 4th quarter worth about $121,000. Finally, Millennium Management LLC increased its stake in shares of enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after acquiring an additional 7,472 shares during the last quarter. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.